A common pigmentation variant tracks faster Parkinson's progression

Design

Longitudinal cohort study with independent replication in three randomised trial cohorts; up to 12 years' follow-up

Population

383 participants with sporadic Parkinson's disease in PPMI, 587 in the replication cohort, 53 with prodromal disease; participants of European descent

Primary outcome

Rate of motor decline on MDS-UPDRS Part III, and phenoconversion in prodromal participants

Effect

Carriers declined 30% faster (0.57 points/year, 95% CI 0.16-0.98; P=.006) and 50% faster in replication (1.37, 0.28-2.46; P=.01); prodromal phenoconversion subdistribution hazard ratio 4.75 (1.48-15.27; P=.009)

MC1R governs pigmentation and sits in oxidative stress pathways that have long been suspected in Parkinson's disease — the same gene behind red hair and the melanoma link. Loss-of-function variants are carried by over 60% of people of European descent, which makes this a common variant rather than a rare one.

In the Parkinson Progression Markers Initiative, 383 participants with sporadic Parkinson's disease were followed for up to 12 years. Carriers declined 30% faster on the motor examination of the MDS-UPDRS (0.57 points per year, 95% CI 0.16-0.98), after adjustment for age at onset, sex, race, baseline score and levodopa equivalent dose. A replication cohort of 587 participants drawn from three randomised trials showed 50% faster decline (1.37 points per year, 0.28-2.46). In a small prodromal group of 53, carriers had more than four times the risk of converting to clinical Parkinson's disease (subdistribution hazard ratio 4.75, 1.48-15.27).

The immediate use is in trials, not in clinic: a large, cheaply genotyped subgroup that progresses faster is exactly what an enrichment strategy needs. The finding does not tell an individual patient anything actionable, and the cohorts were of European descent, which limits what can be said about Indian patients specifically.

• Nothing to order — MC1R genotyping has no clinical role in Parkinson's disease today
• Watch for this as a trial enrichment criterion in future study designs
• Note that the cohorts were of European descent; carriage rates elsewhere differ
• The prodromal result rests on 53 people and should be treated as preliminary
• Do not extend the melanoma-Parkinson's association beyond existing skin surveillance advice

Why it matters

It offers a large, already-genotyped subgroup that progresses faster, which is what trials of disease modification have lacked.

Don't overread it

Observational cohorts in people of European descent — this identifies a marker of faster progression, not a cause of it or a target to treat.

The statistics, in plain English

The effect is a difference in slope: about half a point more per year on a motor scale that runs to 132, which accumulates over a decade but is invisible between two visits. The replication cohort's larger estimate (1.37 points per year) with a wide interval reaching 0.28 shows how imprecise these slopes are. The fourfold phenoconversion hazard comes from 34 carriers and 19 non-carriers, and an interval of 1.48 to 15.27 is consistent with anything from a modest to an enormous effect.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.